Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
TikTok allowed millions of people to see Canadian ‘helicopter’ wildfire conspiracies before taking down videos
Did Fortnite Remove the Kinetic Blade?
Starfield Preload Dates and Times
Disney Plus and Hulu price increases are coming. How to avoid them
Baby Gronk's dad irks Paige Spiranac and Taylor Lewan. What did he do?
How Long to Beat Armored Core 6
How to Get Free UCL/UWCL Hero in EA Sports FC 24
Facebook might start bypassing Apple and Google's app stores in the EU